Tbay has become Nigeria's leading app and website for reliable, fast, and secure gift card trading. It has over a million downloads on the Google Play Store and are continuously growing. Known for its ...

The FTSE 100 closed down 5.71 points at 8166.68. Among the firms with updates today are Marks & Spencer, JD Wetherspoon, ...

Schrödinger, Inc. today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis's portfolio for further development. The ...

And before I hand over to Pascal and other members of the executive team, I would like to cover some important housekeeping ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Andrew Berens gave his rating based on several factors, including AstraZeneca’s strong financial performance in the third quarter of 2024. The company reported total revenues of $13.565 billion, ...

The executive in charge of AstraZeneca operations in China is under detention by Chinese authorities who are investigating employees there, the company said. The disclosure comes after AstraZeneca ...

LONDON, Nov 6 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not know the reason ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

Over the past three years, additional insurance fraud cases have emerged involving AstraZeneca employees in various Chinese regions. The investigation focuses on potential breaches of data privacy ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space.